Clinical spectrum of hereditary hemorrhagic telangiectasia: data from the Comprehensive HHT Outcomes Registry of the US (CHORUS)
Blood · 2026
DOI: 10.1182/blood.2026033112 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Blood, 2026. Verfasst von Hanny Al-Samkari und 42 weiteren Autor:innen. Beteiligte Einrichtung: Division of Classical Hematology, Mass General Brigham Cancer Institute, Massachusetts General Hospital, Harvard Medical School, Boston, MA. Hauptthemen laut MEDLINE: Telangiectasia, Hereditary Hemorrhagic, Registries. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Hereditary hemorrhagic telangiectasia (HHT), an autosomal dominant vasculopathy affecting 1 in 5000 individuals, is the second most common inherited bleeding disorder worldwide. Despite this prevalence, comprehensive data on disease manifestations and complications remain limited. To address this gap, the US Congress allocated funding leading to the Comprehensive HHT Outcomes Registry of the United States (CHORUS), a prospective, 15-center longitudinal registry enrolling unselected patients with confirmed HHT. In this initial report, we describe findings from the first 600 participants, with a median age of 53 (range, 0-88) years and 60% female. Despite most participants developing typical HHT manifestations by age 13 years, the majority (63%) were not diagnosed until mid-to-late adulthood. Recurrent spontaneous epistaxis occurred in 95% of participants, chronic gastrointestinal bleeding in 30%, and heavy menstrual bleeding in 35% of postmenarche females, together resulting in moderate-to-severe mucosal bleeding in 76%. Iron deficiency and/or anemia were diagnosed in 68%, with 41% requiring IV iron and 25% requiring red cell transfusions. Serious complications of solid-organ arteriovenous malformations were frequent, including intracranial hemorrhage (3%), pulmonary hemorrhage (2%), venous thromboembolism (7%), arterial thromboembolism (11%), heart failure (7%), and pulmonary hypertension (7%). These data from CHORUS, the first national US registry of its kind, provide reliable, real-world estimates of the incidence, prevalence, and severity of numerous HHT manifestations and complications. HHT has a high burden of moderate-to-severe bleeding, anemia, thrombosis, and major neurologic and cardiopulmonary complications. There is a mean interval between first symptoms and diagnosis of >2 decades, during which substantial, serious, and preventable HHT morbidity, including early intracranial hemorrhage, may occur. This trial was registered at clinicaltrials.gov as NCT06259292.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Division of Classical Hematology, Mass General Brigham Cancer Institute, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
- Cure HHT, Monkton, MD.
- Division of Hematology/Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC.
- Division of Pulmonary and Critical Care Medicine, Augusta University, Augusta, GA.
- Division of Pulmonary and Critical Care Medicine, Columbia University, New York, NY.
- Division of Pulmonary and Critical Care Medicine, University of Colorado Anschutz, Aurora, CO.
ORCID-Profile: Hanny Al-Samkari, Cassi Friday, Raj S Kasthuri, Charles G Murphy, Vivek Iyer, Vaibhav Ahluwalia, Josanna Rodriguez-Lopez, Miles Conrad, Steven Hetts, Michael Ohliger, Bryan A Sisk, Melissa A Beasley, Jonathan Lindquist, Keith McCrae, Kevin Whitehead, Lucas R Cusumano, Theodore G Drivas, Claire Kaufman, Melissa Dickey, Nolie Krock
Zitieren
APA
Al-Samkari, H., Friday, C., Kasthuri, R. S., Gossage, J. R., Murphy, C. G., Hountras, P., Smith, K. L., Kirkland, K., Iyer, V., Prasad, V., Ahluwalia, V., Rodriguez-Lopez, J., Witkin, A. S., Conrad, M., Hetts, S., Ohliger, M., Chakinala, M., Sisk, B. A., Beasley, M. A., …, & Pollak, J. S. (2026). Clinical spectrum of hereditary hemorrhagic telangiectasia: data from the Comprehensive HHT Outcomes Registry of the US (CHORUS). Blood. https://doi.org/10.1182/blood.2026033112
Vancouver
Al-Samkari H, Friday C, Kasthuri RS, Gossage JR, Murphy CG, Hountras P, et al. Clinical spectrum of hereditary hemorrhagic telangiectasia: data from the Comprehensive HHT Outcomes Registry of the US (CHORUS). Blood. 2026. doi:10.1182/blood.2026033112
BibTeX
@article{AlSamkari2026,
author = {Al-Samkari, Hanny and Friday, Cassi and Kasthuri, Raj S and Gossage, James R and Murphy, Charles G and Hountras, Peter and Smith, Karen L and Kirkland, Kristi and Iyer, Vivek and Prasad, Vikas and Ahluwalia, Vaibhav and Rodriguez-Lopez, Josanna and Witkin, Alison S and Conrad, Miles and Hetts, Steven and Ohliger, Michael and Chakinala, Murali and Sisk, Bryan A and Beasley, Melissa A and Kirkpatrick, Paul and Lindquist, Jonathan and Battaile, John T and Lu, An and Parambil, Joseph and McCrae, Keith and Sheynzon, Vladimir and Whitehead, Kevin and Sion, Cassidy and McWilliams, Justin and Cusumano, Lucas R and Trerotola, Scott O and Drivas, Theodore G and Chesnutt, Mark and Kaufman, Claire and Dickey, Melissa and Boyce, Danielle and Krock, Nolie and Cottrill, Crystal and Competiello, Tania and Levy, Hara and Clancy, Marianne and Henderson, Katharine and Pollak, Jeffrey S},
title = {Clinical spectrum of hereditary hemorrhagic telangiectasia: data from the Comprehensive HHT Outcomes Registry of the US (CHORUS)},
journal = {Blood},
year = {2026},
doi = {10.1182/blood.2026033112}
}
EUVIMED